Research Library

A retrospective case series examining CBD use for anxiety and sleep complaints. Results showed anxiety scores decreased within the first month in 79.2% of patients and remained decreased during the study duration.

Double-blind, placebo-controlled trial of cannabidiol in patients with Dravet syndrome. The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol.

Comprehensive review of preclinical, human experimental, clinical, and epidemiological studies supporting CBD as a treatment for anxiety disorders including GAD, SAD, PD, OCD, and PTSD.

Study demonstrating that transdermal CBD application has therapeutic potential for relief of arthritis pain-related behaviors and inflammation without evident side effects.

Prospective study showing that CBD-enriched cannabis is a promising treatment option for refractory behavioral problems in children with ASD.

Open-label, expanded access program showing cannabidiol was generally well tolerated and reduced seizure frequency in highly treatment-resistant epilepsy.

Systematic review of 47 studies examining CBD for chronic pain. Evidence suggests CBD may be effective for neuropathic and inflammatory pain with minimal adverse effects.

Double-blind study showing that pretreatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in speech performance in patients with social anxiety disorder.

CBD reduced cue-induced craving and anxiety in individuals with heroin use disorder. Findings suggest CBD may be a treatment option for opioid addiction.

Review examining CBD for IBD treatment. While preclinical evidence is promising, more high-quality RCTs are needed to establish efficacy in humans.

Comprehensive review of CBD's neuroprotective properties relevant to Alzheimer's, Parkinson's, and Huntington's diseases through antioxidant and anti-inflammatory mechanisms.

Review of CBD's effects on sleep. Evidence suggests CBD may improve sleep quality and duration, particularly in individuals with anxiety-related sleep disturbances.

Double-blind RCT showing CBD as adjunctive therapy significantly improved positive psychotic symptoms and was well-tolerated in patients with schizophrenia.

Retrospective chart review of PTSD patients treated with CBD. Results showed significant reduction in PTSD symptom severity in 91% of patients.

Review of CBD's cardiovascular effects. Evidence suggests CBD may reduce blood pressure, improve endothelial function, and provide cardioprotective benefits.

Preclinical study demonstrating CBD's antiemetic effects. CBD reduced nausea and vomiting in animal models through serotonin receptor activation.

Laboratory study showing CBD has anti-inflammatory and sebostatic effects on human sebocytes, suggesting therapeutic potential for acne treatment.

Comprehensive review of CBD drug interactions. CBD inhibits CYP450 enzymes, potentially affecting metabolism of various medications including anticoagulants and antiepileptics.

Long-term safety study of CBD in epilepsy patients. CBD was generally well-tolerated over 12 months with most adverse events being mild to moderate.

Meta-analysis of 79 trials examining cannabinoids for MS. Moderate-quality evidence supports CBD for reducing spasticity and pain in MS patients.